February, 2025
February 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
2425262728  
Subcutaneous vs Intravenous Trastuzumab/Pertuzumab in HER2+ Breast Cancer
Jul 25, 2024, 20:48

Subcutaneous vs Intravenous Trastuzumab/Pertuzumab in HER2+ Breast Cancer

Dana-Farber’s Breast Oncology Center shared on X:

“New in JCO Oncology Practice:

Subcutaneous vs Intravenous Trastuzumab/Pertuzumab: A Time and Motion Substudy of a Phase II Trial of Adjuvant Trastuzumab/Pertuzumab for Stage I HER2+ Breast Cancer (ADEPT trial).

Full Text here.”

Source: Dana-Farber’s Breast Oncology Center/X

Breast Cancer

Authors: Adrienne G Waks, Emily L Chen, Noah Graham, Anna Mae Frey, Kenneth Almeida, Victoria Attaya, Cari Ryding, Ibrahim Abbass, Anita Fung, Jesse Sussell, Patricia Cortazar, Caroline Harvey, Denise Leth, Meredith Faggen, Natalie Sinclair, Jeanna Walsh, Nadine Tung, Sarah Sinclair, Steve Lo, Denise Yardley, Vicente Valero, Jane Meisel, Tarah J Ballinger, Sylvia Adams, Lisa A Carey, Julia K Rauch, Vandana G Abramson, Nicole O Williams, Wendy Y Chen, Jose P Leone, Susan T Schumer, Nabihah Tayob, Sara M Tolaney

Subcutaneous vs Intravenous Trastuzumab/Pertuzumab: A Time and Motion Substudy of a Phase II Trial of Adjuvant Trastuzumab/Pertuzumab for Stage I HER2+ Breast Cancer (ADEPT trial)